Growth Metrics

Quest Diagnostics (DGX) Cash from Financing Activities (2016 - 2026)

Quest Diagnostics' Cash from Financing Activities history spans 18 years, with the latest figure at -$152.0 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 72.91% to -$152.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$979.0 million, a 244.82% decrease, with the full-year FY2025 number at -$1.4 billion, down 228.04% from a year prior.
  • Cash from Financing Activities hit -$152.0 million in Q1 2026 for Quest Diagnostics, up from -$287.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for DGX hit a ceiling of $1.8 billion in Q3 2024 and a floor of -$561.0 million in Q1 2025.
  • Historically, Cash from Financing Activities has averaged -$119.3 million across 5 years, with a median of -$242.0 million in 2022.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 1147.37% in 2022 and later skyrocketed 2232.53% in 2024.
  • Tracing DGX's Cash from Financing Activities over 5 years: stood at -$545.0 million in 2022, then surged by 123.85% to $130.0 million in 2023, then crashed by 230.77% to -$170.0 million in 2024, then crashed by 68.82% to -$287.0 million in 2025, then surged by 47.04% to -$152.0 million in 2026.
  • Business Quant data shows Cash from Financing Activities for DGX at -$152.0 million in Q1 2026, -$287.0 million in Q4 2025, and -$247.0 million in Q3 2025.